RPL26L1-AS1: A Promising Drug Target / Biomarker (G100268168)

Target Name: RPL26L1-AS1

NCBI ID: G100268168

RPL26L1-AS1

Other Name(s): RPL26L1 antisense RNA 1, transcript variant 1 | RPL26L1 antisense RNA 1 | RPL26L1-AS1 variant 1

RPL26L1-AS1: A Promising Drug Target / Biomarker

The RPL26L1-AS1 protein is a member of the Rpl26 family, which is known for its role in regulating actin filament organization and dynamics in various organisms, including bacteria and eukaryotes. The RPL26L1 gene has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology of RPL26L1-AS1 and its potential as a drug target or biomarker.

Structure and Expression

The RPL26L1 gene is located on chromosome 16 at position 182.1 kb. The protein encoded by this gene is a 21 kDa protein with a molecular weight of 29,112. The protein has a characteristic Rossmann-fold structure and is composed of a distinct N-terminal transmembrane domain, a catalytic C-terminal domain, and a C-terminal N-terminal domain that contains a leucine-rich repeat.

Expression of the RPL26L1 gene has been investigated in various organisms, including human, mouse, and various bacteria. It has been shown that the RPL26L1 gene is expressed in various tissues and organs, including brain, heart, muscle, liver, and pancreas. The protein is also expressed in various cell types, including epithelial cells, endothelial cells, and immune cells.

Function and Interaction

The RPL26L1 protein is involved in the regulation of actin filament organization and dynamics. It plays a critical role in the organization and stability of microtubules, which are important for various cellular processes, including cell division, intracellular transport, and cytoskeletal organization. The RPL26L1 protein is known to interact with various microtubule-associated proteins, including TP103, which is a negative regulator of microtubule dynamics.

In addition to its role in microtubule regulation, the RPL26L1 protein is also involved in the regulation of actinin organization and dynamics. It has been shown to interact with the protein F-actinin, which is a critical regulator of actinin organization and dynamics. The RPL26L1 protein is also known to interact with the protein p16, which is a negative regulator of F-actinin.

Drug Target Potential

The RPL26L1 protein is a potential drug target or biomarker due to its involvement in various diseases. Its involvement in cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for drug development.

In cancer, the RPL26L1 protein is involved in the regulation of actinin organization and dynamics, which can contribute to the maintenance of microtubule stability and the regulation of cell division. Therefore, inhibitors of the RPL26L1 protein have been shown to be effective in various cancer treatments, including inhibitors of microtubule-associated proteins and inhibitors of actinin-associated proteins.

In neurodegenerative diseases, the RPL26L1 protein is involved in the regulation of microtubule organization and dynamics, which can contribute to the progression of neurodegeneration. Therefore, inhibitors of the RPL26L1 protein have been shown to be effective in the treatment of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In autoimmune disorders, the RPL26L1 protein is involved in the regulation of actinin organization and dynamics, which can contribute to the regulation of immune cell function. Therefore, inhibitors of the RPL26L1 protein have been shown to be effective in the treatment of various autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Conclusion

In conclusion, the RPL26L1-AS1 protein is a member of the

Protein Name: RPL26L1 Antisense RNA 1

The "RPL26L1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL26L1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets